Published • loading... • Updated
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Summary by Hastings Tribune
3 Articles
3 Articles
Hastings TribuneReposted by 
Rutland Herald
Rutland HeraldNovocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Jun 30, 2026-
·Nebraska, United States
Read Full Article
Novocure receives CE mark for Optune Pax device
Novocure has received CE Mark for Optune Pax, its portable medical device intended to treat adults with locally advanced pancreatic cancer of exocrine origin.The post Novocure receives CE mark for Optune Pax device appeared first on Hospital Management.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
